Hologic Aktie
72,60USD | -0,13USD | -0,18% |
WKN: 879100 / ISIN: US4364401012
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 98,57 |
The Vanguard Group, Inc. | 12,20 |
Vanguard Group, Inc. (Subfiler) | 11,42 |
T. Rowe Price Investment Management, Inc. | 9,75 |
T. Rowe Price Investment Management, Inc. | 9,75 |
T Rowe Price Mid Cap Growth Fund | 4,63 |
State Street Corp. | 4,59 |
Morgan Stanley Investment Management Ltd. | 3,92 |
BlackRock Fund Advisors | 3,76 |
Vanguard Total Stock Market ETF | 3,24 |
Vanguard 500 Index Fund | 2,71 |
Geode Capital Management LLC | 2,46 |
BlackRock Institutional Trust Co. NA | 2,27 |
Vanguard Mid Cap Index Fund | 2,17 |
Fidelity Management & Research Co. LLC | 2,16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 5 814 | 6 705 | 6 944 | 6 990 | 7 063 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,65 | 0,84 | 0,70 | 0,58 | 0,57 |
Bilanz (in Mio. USD) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 2 222 | 3 169 | 3 862 | 4 185 | 3 823 |
Summe Anlagevermögen | 4 974 | 5 751 | 5 209 | 4 955 | 5 333 |
Summe Aktiva | 7 196 | 8 920 | 9 071 | 9 139 | 9 156 |
Bilanz (in Mio. USD) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 4 489 | 4 701 | 4 195 | 4 122 | 4 026 |
Summe Eigenkapital | 2 707 | 4 219 | 4 876 | 5 017 | 5 130 |
Summe Passiva | 7 196 | 8 920 | 9 071 | 9 139 | 9 156 |
Adresse
250 Campus Drive, 01752 Marlborough | |
Telefon | +1 (508) 263-2900 |
Internet | http://www.hologic.com |
Management
Amy A. McBride-Wendell
Lead Independent Director |
Benjamin J. Cohn
Vice President & Controller |
Charles J. Dockendorff
Independent Director |
Christiana Stamoulis
Independent Director |
Diana de Walt
Senior Vice President-Global Human Resources |
Essex D. Mitchell
Chief Operating Officer |
Jan Verstreken
Group President-International |
Jennifer Schneiders
President-Diagnostics Solutions |
John M. Griffin
General Counsel |
Karleen Marie Oberton
Chief Financial Officer |
Ludwig N. Hantson
Independent Director |
Mark W Irving
Secretary & Vice President |
Martin D. Madaus
Director |
Monica Aguirre Berthelot
Chief of Staff & Vice President |
Nanaz Mohtashami
Independent Director |
Paul Malenchini
Chief Information Officer |
Ryan Simon
Vice President-Investor Relations |
Sally W. Crawford
Independent Director |
Scott Christensen
SVP-Global Supply Chain, Quality & Regulatory |
Scott T. Garrett
Independent Director |
Stacey D. Stewart
Independent Director |
Stephen P. MacMillan
Chairman, President & Chief Executive Officer |